吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及炎性因子的影响

Effect of pioglitazone and metformin on insulin resistance and inflammatory factors in type 2 diabetic patients

目的观察吡格列酮及二甲双胍联合治疗2型糖尿病对患者胰岛素抵抗指数与炎性因子水平的影响。方法94例2型糖尿病患者随机分为观察组和对照组,分别给予吡格列酮联合二甲双胍、二甲双胍治疗12周,观察治疗前后胰岛素抵抗指数和炎性因子水平,评价治疗效果。结果观察组疗效优于对照组(Hc=6.513,P<0.05),治疗后两组患者胰岛素抵抗指数明显降低,且观察组指标降低更为显著(P<0.01),观察组治疗后超敏C反应蛋白、IL-6水平显著降低,且均低于对照组(P<0.01)。结论吡格列酮及二甲双胍联合治疗2型糖尿病可改善胰岛素抵抗、降低炎性因子水平。

Objective To observe the effect of pioglitazone and metformin on insulin resistance（IR） index and inflammatory factor level in patients with type 2 diabetes mellitus（T2DM）. Methods Ninety-four patients with T2DM were randomly treated with pioglitazone plus metformin（observation group） or metformin（control group） for 12 weeks. IR index,inflammatory factor level, and clinical efficacy were compared between two groups before and after treatment. Results Clinical efficacy was better in observation group than in control group（Hc=6.5131, P〈0.05）. IR index was lowered in both groups after treatment, especially in observation group（P〈0.01）, while hypersensitive C-reactive protein and IL-6 level was decreased only in observation group（P〈0.01）. Conclusion Combined use of pioglitazone and metformin can improve IR and reduce inflammatory factor level in patients with T2DM.